GlaxoSmithKline (GSK.L) is to buy out its partner in a Chinese flu vaccine joint venture, in a move to expand its vaccines presence in a key emerging market.
The drugmaker said on Tuesday it would pay 24 million pounds ($39 million) to acquire the remaining 51 percent stake held by Shenzhen Neptunus Interlong Bio-Technique (8329.HK) in the joint company, Shenzhen GSK-Neptunus Biologicals (GSKNB).
